Practical Considerations for Demonstrating Drug Substance Uniformity - The authors describe considerations and best practices for meeting drug substance uniformity. - BioPharm International


Practical Considerations for Demonstrating Drug Substance Uniformity
The authors describe considerations and best practices for meeting drug substance uniformity.

BioPharm International
Volume 24, Issue 4, pp. 30-37

Requirements at or tighter than the DS specification limits

Table I: Typical processing steps in drug substance filtration operation. (FIGURE IS COURTESY OF THE AUTHOR)
The criteria for DS uniformity may be established to be the same as the DS specification limits. While this is a relatively simple way of setting the uniformity process validation acceptance criteria (PVAC), it does carry the undesirable risk of failure for DP specification and uniformity limits if the sample measurements are at the DS specification limits, especially if there are stability concerns during storage. One way to reduce this risk is to set the validation acceptance criteria within the DS specification limits, thereby providing a safety margin. One should also ensure that the documented analytical method precision is able to achieve results of the reduced range. The advantage of this approach is its simplicity in applying a safety margin relative to the specification limits, which ensures robustness in meeting the process needs. The downside is that the safety margin allowance may be subjective and may not align with the method precision.

Inclusion of analytical method variance (to account for potential measurement error)

This strategy takes into consideration all potential errors that could contribute variability to the uniformity results, such as analytical method variability and volume measurement for the product and additives, in order to ensure acceptable DS uniformity. The root mean squares of the potential errors are calculated to derive the acceptance criteria. The acceptance criteria may be established based on the analytical method variability or precision when the analytical method variance is significantly greater (more than one order of magnitude) than the process variance. It should be emphasized that the prospective method validation acceptance criteria should be used in the calculation, rather than the results from the analytical method validation exercise. One must also ensure that sound technical justification exists for how the method validation acceptance criteria are developed. The latter is typically based on a fairly small data set and could result in overly tight acceptance criteria, resulting in a failure of the uniformity study. The acceptance criteria is set so that the percentage relative standard deviation (RSD) of the sample points is less than or equal to the analytical method precision. An assessment on process impact in using this method is recommended to ensure that validation acceptance criteria are not set too wide.

Percentage of the feed stream concentration

Figure 2: Concentration curves for surrogate (0.1 M NaCl) and product filtrations. (FIGURE IS COURTESY OF THE AUTHOR)
Another simple way to establish uniformity study validation acceptance criteria is to evaluate individual samples against a percentage of the feed material concentration. Selection of the actual percentage value could use a similar approach to that described the two previous methods. This method is based on the assumption that typically, there may be a small amount of product adsorption onto the bulk filter or dilution from flush water/buffer retained in the filter apparatus. As such, this source of variability is expected during the initial phase of the bulk filtration step. This method is applicable where the principal uniformity failure mode is based on dilution. It is fairly simple to implement, but can be problematic if the method variability is high.

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here